# STOCKHOLM 1.0
#=GF ID   Pentaxin
#=GF AC   PF00354.21
#=GF DE   Pentaxin family
#=GF PI   pentaxin; 
#=GF AU   Finn RD;0000-0001-8626-2148
#=GF SE   Prosite
#=GF GA   25.00 25.00;
#=GF TC   25.00 25.00;
#=GF NC   24.90 24.90;
#=GF BM   hmmbuild HMM.ann SEED.ann
#=GF SM   hmmsearch -E 1000 -Z 75585367 --cpu 4 HMM pfamseq
#=GF TP   Domain
#=GF WK   Pentraxins
#=GF CL   CL0004
#=GF RN   [1]
#=GF RM   7772283
#=GF RT   Structure and function of the pentraxins. 
#=GF RA   Gewurz H, Zhang XH, Lint TF; 
#=GF RL   Curr Opin Immunol 1995;7:54-64.
#=GF RN   [2]
#=GF RM   7881902
#=GF RT   Comparative analyses of pentraxins: implications for protomer
#=GF RT   assembly and ligand binding. 
#=GF RA   Srinivasan N, White HE, Emsley J, Wood SP, Pepys MB, Blundell
#=GF RA   TL; 
#=GF RL   Structure 1994;2:1017-1027.
#=GF RN   [3]
#=GF RM   8114934
#=GF RT   Structure of pentameric human serum amyloid P component. 
#=GF RA   Emsley J, White HE, O'Hara BP, Oliva G, Srinivasan N, Tickle IJ,
#=GF RA   Blundell TL, Pepys MB, Wood SP; 
#=GF RL   Nature 1994;367:338-345.
#=GF DR   INTERPRO; IPR001759;
#=GF DR   PROSITE; PDOC00261;
#=GF DR   PRINTS; PR00895;
#=GF DR   SCOP; 1sac; fa;
#=GF DR   HOMSTRAD; pentraxin;
#=GF DR   SO; 0000417; polypeptide_domain;
#=GF CC   Pentaxins are also known as pentraxins.
#=GF SQ   8
#=GS SAMP_MOUSE/27-220    AC P12246.2
#=GS SAMP_HUMAN/26-219    AC P02743.2
#=GS FP_CRIMI/26-219      AC P15697.1
#=GS CRP_HUMAN/25-220     AC P02741.1
#=GS CRP_RABIT/26-221     AC P02742.1
#=GS Q542I3_MOUSE/26-221  AC Q542I3.1
#=GS CRP1_LIMPO/33-237    AC P06205.1
#=GS CRP_XENLA/23-219     AC Q07203.1
SAMP_MOUSE/27-220               KVFVFPRESETDHVKLIPHLEKP.LQNFTLCFRTYSD.LS..RSQSLFSYSVKG..RDNELLIYKEKVGEYSLYIGQSKVTVRGMEEYL...SPVHLCTTWESSSGIVEFWVNGKPWVKKSLQREYTVKAPPS....IVLGQEQDNYGGGFQRSQSFVGEFSDLYMWDYVLTPQDILFVYRDSP.....VNPNILNWQALNYEINGYVVIRP
SAMP_HUMAN/26-219               KVFVFPRESVTDHVNLITPLEKP.LQNFTLCFRAYSD.LS..RAYSLFSYNTQG..RDNELLVYKERVGEYSLYIGRHKVTSKVIEKFP...APVHICVSWESSSGIAEFWINGTPLVKKGLRQGYFVEAQPK....IVLGQEQDSYGGKFDRSQSFVGEIGDLYMWDSVLPPENILSAYQGTP.....LPANILDWQALNYEIRGYVIIKP
FP_CRIMI/26-219                 KVFVFPRESESDYVKLIPRLEKP.LENFTLCFRTYTD.LS..RPHSLFSYNTKN..KDNELLIYKERMGEYGLYIENLGAIVRGVEEFA...SPVHFCTSWESSSGIAEFWVNGIPWVKKGLKKGYTVKTQPS....IILGQEQDNYGGGFDKSQSFVGEMGDLNMWDSVLTPEEIKSVYEGSW.....LEANILDWRTLNYEMSGYAVIRP
CRP_HUMAN/25-220                KAFVFPKESDTSYVSLKAPLTKP.LKAFTVCLHFYTE.LSSTRGYSIFSYATKR..QDNEILIFWSKDIGYSFTVGGSEILFEVPEVTV...APVHICTSWESASGIVEFWVDGKPRVRKSLKKGYTVGAEAS....IILGQEQDSFGGNFEGSQSLVGDIGNVNMWDFVLSPDEINTIYLGGP.....FSPNVLNWRALKYEVQGEVFTKP
CRP_RABIT/26-221                KAFVFPKESDNSYVSLNAQLKKP.LKAFTVCLYFYTD.LSMTRGYSIFSYATRR..QFNEILLFWSKDIGYSFSVGGDEIIFKVSDIPV...DPTHLCASWESSTGIAELWVDGKPMVRKSLKKGYILGPEAS....IILGQDQDSFGGSFEKQQSLVGDIGNVNMWDYALSPEEINTIYAGGT.....FSPNVLDWRELTYQVRGEVHVKP
Q542I3_MOUSE/26-221             KAFVFPKESDTSYVSLEAESKKP.LNTFTVCLHFYTA.LSTVRSFSVFSYATKK..NSNDILIFWNKDKQYTFGVGGAEVRFMVSEIPE...APTHICASWESATGIVEFWIDGKPKVRKSLHKGYTVGPDAS....IILGQEQDSYGGDFDAKQSLVGDIGDVNMWDFVLSPEQISTVYVGGT.....LSPNVLNWRALNYKAQGDVFIKP
CRP1_LIMPO/33-237               KV.KFPPSSSPSFPRLVMVGTLPDLQEITLCYWFKVNRLK..GTLHMFSYATAK..KDNELLTLIDEQGDFLFNVHGAPQLKVQCPNKIHIGKWHHVCHTWSSWEGEATIAVDG..FHCKGNATGIAVGRTLSQGGLVVLGQDQDSVGGKFDATQSLEGELSELNLWNTVLNHEQIKYLSKCAHPSERHIYGNIIQWDKTQFKAYDGVVLSP
CRP_XENLA/23-219                NVFLFPKPSVTTYAILKPEVEKP.LKNLTVCLRSYTT.LT..RFHSLLSLATSNPLQDNAFLLFSKPPNQCSIYINQEENVFKVDPTAV...EWKHTCVSWDSVSGVVELWIDGKLYPRTVSKKASSIGFPSS....IIQGQEQDSFGGGFNIDQSFVGEISDVHMWDYVLTPDHIQKVLFANMD....FNGNIISWRSLQYELRGQATTQP
#=GC seq_cons                   KVFVFP+ES-ToYVpLhspLcKP.LpsFTlCh+hYT-.LS..RuaSlFSYAT+p..pDNElLlahc+sspYShhlGsscllh+VsEphl...uPsHlCsSWESuSGIsEFWVDGKPhV+KuL+KGYoVGspsS....IILGQEQDSaGGsF-toQShVGEIGDlNMWDaVLoPEcIpolYtGus.....lssNILsWRuLsYElpGtVhl+P
